IN8bio (INAB) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
IN8bio (INAB) has outperformed Pluri (PLUR) over the past year, losing 42.7% versus a loss of 75.5%. Over five years, PLUR leads with a -95.2% price change compared with -99.2% for INAB. IN8bio is the larger company by market cap ($13.6 million vs $12.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | PLUR |
|---|---|---|
| Share price | $1.38 | $1.00 |
| Market cap | $13.60M | $12.61M |
| 1-day change | -1.43% | -3.85% |
| YTD return | -41.03% | -66.56% |
| 1-year return | -42.74% | -75.49% |
| 5-year return | -99.23% | -95.23% |
| EPS (TTM) | $-1.62 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $4.87 |
| 52-week low | $0.88 | $0.85 |
| Distance from 52-week high | -49.45% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +407.25% | — |
| Average volume | 58.36K | 25.99K |
| Shares outstanding | 9.86M | 12.61M |
| Employees | 18 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed PLUR by 32.8 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Healthcare · Biotechnology · 18 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
INAB vs PLUR FAQ
Which is bigger, IN8bio or Pluri?
IN8bio (INAB) is larger, with a market capitalization of $13.60M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, INAB or PLUR?
INAB returned -42.74% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.